Myeloid immune cells

Myeloid immune cells are a diverse lineage of hematopoietic cells originating from common myeloid progenitors in the bone marrow, encompassing neutrophils, monocytes, macrophages, dendritic cells, eosinophils, and basophils [1]. These cells serve as the primary effectors of the innate immune system, providing rapid defense against pathogens through phagocytosis, the release of antimicrobial granules, and the production of inflammatory signaling molecules [2]. They also play a vital role in bridging innate and adaptive immunity by acting as professional antigen-presenting cells that activate T and B lymphocytes [3]. In various diseases, myeloid cells can become dysregulated; for instance, in chronic inflammation, they drive tissue damage, while in the tumor microenvironment, they often adopt immunosuppressive roles that facilitate cancer progression [4]. Therapeutic strategies often focus on modulating specific receptors or signaling pathways within these cells, such as CSF1R or CD47, rather than targeting the entire myeloid population as a single entity [5]. Because the term Myeloid immune cells describes a broad biological category of cells rather than a specific protein or receptor, it is not classified as a single therapeutic target in the molecular sense [5]. Monitoring these cells is frequently performed via flow cytometry using surface markers like CD11b or CD33 to assess immune status or treatment response [1]. Overall, while they are essential for host defense, they represent a complex, multi-target environment in modern drug development rather than a discrete target molecule [4].

Other names

Myeloid cellsMyeloid lineageMyelocytesInnate immune myeloid cells

Modulation of myeloid cell production, recruitment, or activity via specific molecular targets such as G-CSF receptors, CSF1R, or CD47.